Kritische 8-K Meldungen
HOCH Abgang Schlüsselpersonen (06.02.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 06.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ☒ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment o |
| 03.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ☒ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment o |
| 18.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | m 8-K and is incorporated herein by reference. Item 5.02. Departure of Directors or Certain Officers; Election of Direct |
| 13.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | f the Exchange Act. ☒ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 28.11.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ☒ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment o |
| 23.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ology and Apexigen publicly file with the SEC. Item 5.02 Departure of Directors or Certain Officers; Election of Directo |
| 30.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ☒ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of C |
| 24.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | erein by reference. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 28.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ☒ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce |
| 22.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | eneral incorporation language in such filings. Item 5.02 Departure of Directors or Certain Officers; Election of Directo |
Stammdaten
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | Pyxis Oncology, Inc. |
|---|---|
| Ticker | PYXS |
| CIK | 0001782223 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 104,9 Mio. USD |
| Beta | 1,42 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 13,858,000 | -79,621,000 | -1.28 | 91,520,000 | 53,408,000 |
| 2025-09-30 | 10-Q | 2,820,000 | -22,003,000 | -0.35 | 105,604,000 | 68,779,000 |
| 2025-06-30 | 10-Q | 2,820,000 | -18,354,000 | -0.30 | 123,215,000 | 87,643,000 |
| 2025-03-31 | 10-Q | -21,158,000 | -0.35 | 135,867,000 | 103,103,000 | |
| 2024-12-31 | 10-K | 16,146,000 | -77,331,000 | -1.32 | 157,181,000 | 120,751,000 |
| 2024-09-30 | 10-Q | 16,146,000 | -21,203,000 | -0.35 | 195,311,000 | 153,680,000 |
| 2024-06-30 | 10-Q | 16,146,000 | -17,301,000 | -0.29 | 208,389,000 | 169,794,000 |
| 2024-03-31 | 10-Q | 16,146,000 | -3,256,000 | -0.06 | 220,220,000 | 184,156,000 |
| 2023-12-31 | 10-K | -73,790,000 | -1.85 | 173,726,000 | 125,704,000 | |
| 2023-09-30 | 10-Q | -23,049,000 | -0.56 | 186,692,000 | 137,946,000 | |
| 2023-06-30 | 10-Q | -15,901,000 | -0.41 | 175,230,000 | 145,275,000 | |
| 2023-03-31 | 10-Q | -19,243,000 | -0.54 | 182,803,000 | 152,163,000 | |
| 2022-12-31 | 10-K | -120,717,000 | -3.65 | 211,379,000 | 160,824,000 | |
| 2022-09-30 | 10-Q | -27,674,000 | -0.85 | 223,895,000 | 188,747,000 | |
| 2022-06-30 | 10-Q | -25,562,000 | -0.79 | 242,563,000 | 211,966,000 | |
| 2022-03-31 | 10-Q | -31,380,000 | -0.97 | 252,701,000 | 233,514,000 | |
| 2021-12-31 | 10-K | -75,975,000 | -8.95 | 280,021,000 | 261,313,000 | |
| 2021-09-30 | 10-Q | -14,175,000 | -8.96 | 139,488,000 | -71,439,000 | |
| 2021-06-30 | 10-Q | -8,146,000 | -5.54 | -57,588,000 | ||
| 2021-03-31 | 10-Q | -36,825,000 | -50,017,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.